Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling.

GPRC5A is a G-protein-coupled receptor expressed in lung tissue but repressed in most human lung cancers. Studies in Gprc5a(-/-) mice have established its role as a tumor-suppressor function in this setting, but the basis for its role has been obscure. Here, we report that GPRC5A functions as a negative modulator of EGFR signaling. Mouse tracheal epithelial cells (MTEC) from Gprc5a(-/-) mice exhibited a relative increase in EGFR and downstream STAT3 signaling, whereas GPRC5A expression inhibited EGFR and STAT3 signaling. GPRC5A physically interacted with EGFR through its transmembrane domain, which was required for its EGFR inhibitory activity. Gprc5a(-/-) MTEC were much more susceptible to EGFR inhibitors than wild-type MTEC, suggesting their dependence on EGFR signaling for proliferation and survival. Dysregulated EGFR and STAT3 were identified in the normal epithelia of small and terminal bronchioles as well as tumors of Gprc5a(-/-) mouse lungs. Moreover, in these lungs EGFR inhibitor treatment inhibited EGFR and STAT3 activation along with cell proliferation. Finally, overexpression of ectopic GPRC5A in human non-small cell lung carcinoma cells inhibited both EGF-induced and constitutively activated EGFR signaling. Taken together, our results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis. Cancer Res; 75(9); 1801-14. ©2015 AACR.

[1]  Gregory A. Wyant,et al.  Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1 , 2015, Science.

[2]  Wei Liu,et al.  Proline metabolism and cancer: emerging links to glutamine and collagen , 2014, Current opinion in clinical nutrition and metabolic care.

[3]  G. Superti-Furga,et al.  SLC38A9 is a component of the lysosomal amino acid-sensing machinery that controls mTORC1 , 2014, Nature.

[4]  S. Estrach,et al.  CD98hc (SLC3A2) loss protects against ras-driven tumorigenesis by modulating integrin-mediated mechanotransduction. , 2014, Cancer research.

[5]  Y. Bhutia,et al.  The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy , 2014 .

[6]  B. Han,et al.  EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer , 2014, Molecular Cancer.

[7]  G. Semenza,et al.  Hypoxia-inducible factors enhance glutamate signaling in cancer cells , 2014, Oncotarget.

[8]  N. Samadi,et al.  Akt and p53R2, partners that dictate the progression and invasiveness of cancer. , 2014, DNA repair.

[9]  J. Rasko,et al.  Targeting glutamine transport to suppress melanoma cell growth , 2014, International journal of cancer.

[10]  R. Chen,et al.  The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation , 2014, The Journal of cell biology.

[11]  Timothy D. Johnson,et al.  Macroscopic Stiffness of Breast Tumors Predicts Metastasis , 2014, Scientific Reports.

[12]  Jae-Hoon Chang,et al.  Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. , 2014, Immunity.

[13]  B. Gary,et al.  Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention , 2014, Medicinal Chemistry Research.

[14]  R. Rola,et al.  Glutamate and its receptors in cancer , 2014, Journal of Neural Transmission.

[15]  J. Arthur,et al.  The Catalytic Subunit of the System L1 Amino Acid Transporter (Slc7a5) Facilitates Nutrient Signalling in Mouse Skeletal Muscle , 2014, PloS one.

[16]  Y. Kanai,et al.  JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. , 2014, Journal of pharmacological sciences.

[17]  A. Hartmann,et al.  Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11 , 2014, Clinical Cancer Research.

[18]  N. Siafakas,et al.  Molecular profiling of EGFR family in chronic obstructive pulmonary disease: correlation with airway obstruction , 2013, European journal of clinical investigation.

[19]  Hong-Yang Wang,et al.  MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. , 2013, Gastroenterology.

[20]  M. Verschoor,et al.  Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer , 2013, Molecular Cancer.

[21]  J. Gray,et al.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.

[22]  J. Locasale Serine, glycine and one-carbon units: cancer metabolism in full circle , 2013, Nature Reviews Cancer.

[23]  A. Karameris,et al.  Increased Expression of Epidermal Growth Factor Receptor (EGF-R) in Patients with Different Forms of Lung Fibrosis , 2013, BioMed research international.

[24]  A. Edinger,et al.  Nutrient transporters: the Achilles’ heel of anabolism , 2013, Trends in Endocrinology & Metabolism.

[25]  D. Fotiadis,et al.  The SLC3 and SLC7 families of amino acid transporters. , 2013, Molecular aspects of medicine.

[26]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[27]  P. Kalivas,et al.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. , 2013, Antioxidants & redox signaling.

[28]  A. Lane,et al.  Control of Glutamine Metabolism By the Tumor Suppressor Rb , 2013, Oncogene.

[29]  M. Malumbres,et al.  HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. , 2012, Molecular cell.

[30]  Edward S. Kim,et al.  g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Y. Jeng,et al.  CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation , 2012, Cell Death and Differentiation.

[32]  W. Pao,et al.  Chipping away at the lung cancer genome , 2012, Nature Medicine.

[33]  R. Lotan,et al.  Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation , 2012, Molecular Cancer.

[34]  V. Ganapathy,et al.  SLC6A14 (ATB0,+) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast Cancer* , 2011, The Journal of Biological Chemistry.

[35]  Guoqiang Chen,et al.  MicroRNA‐26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11 , 2011, FEBS letters.

[36]  Z. Bacso,et al.  miR‐126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5 , 2011, FEBS letters.

[37]  M. Ohmura,et al.  CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. , 2011, Cancer cell.

[38]  R. Lotan,et al.  Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. , 2010, Cancer research.

[39]  T. Goldkorn,et al.  Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke. , 2010, American journal of respiratory cell and molecular biology.

[40]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[41]  R. Lotan,et al.  Knockout of the Tumor Suppressor Gene Gprc5a in Mice Leads to NF-κB Activation in Airway Epithelium and Promotes Lung Inflammation and Tumorigenesis , 2010, Cancer Prevention Research.

[42]  S. Wakana,et al.  xCT deficiency accelerates chemically induced tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[43]  P. Blower,et al.  Pharmacogenomic Approach Reveals a Role for the xc− Cystine/Glutamate Antiporter in Growth and Celastrol Resistance of Glioma Cell Lines , 2010, Journal of Pharmacology and Experimental Therapeutics.

[44]  Chi V Dang,et al.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. , 2010, Cancer research.

[45]  Y. Kanai,et al.  l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth , 2010, Cancer science.

[46]  J. Fostel,et al.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis , 2009, Molecular Cancer.

[47]  Suimin Qiu,et al.  Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. , 2009, Cancer cell.

[48]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[49]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[50]  N. Sunaga,et al.  l‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms , 2008, Cancer science.

[51]  D. Munn,et al.  Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. , 2008, The Biochemical journal.

[52]  L. Dwyer-Nield,et al.  Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice , 2008, Cancer Chemotherapy and Pharmacology.

[53]  Yuzhuo Wang,et al.  The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance , 2008, British Journal of Cancer.

[54]  I. Wistuba,et al.  Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer , 2008, PloS one.

[55]  Jonghwan Kim,et al.  Global Identification of Myc Target Genes Reveals Its Direct Role in Mitochondrial Biogenesis and Its E-Box Usage In Vivo , 2008, PloS one.

[56]  Ron Bose,et al.  Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface , 2007, Nature.

[57]  R. Lotan,et al.  Identification of the Retinoic Acid – Inducible Gprc5a as a New Lung Tumor Suppressor Gene , 2022 .

[58]  H. Sontheimer,et al.  Autocrine glutamate signaling promotes glioma cell invasion. , 2007, Cancer research.

[59]  M. Meyerson,et al.  Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. , 2007, Cancer cell.

[60]  David J Riese,et al.  Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[61]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[62]  Y. E. Chin,et al.  Stat3 Cleavage by Caspases , 2006, Journal of Biological Chemistry.

[63]  R. Issels,et al.  The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death , 2006, Oncogene.

[64]  Satoru Takahashi,et al.  Redox Imbalance in Cystine/Glutamate Transporter-deficient Mice* , 2005, Journal of Biological Chemistry.

[65]  Ying Huang,et al.  Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. , 2005, Cancer research.

[66]  A. Hartmann,et al.  Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. , 2005, International journal of oncology.

[67]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[68]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[69]  W. R. Bishop,et al.  Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target* , 2005, Journal of Biological Chemistry.

[70]  S. Shapiro,et al.  Normal lung development in RAIG1-deficient mice despite unique lung epithelium-specific expression. , 2005, American journal of respiratory cell and molecular biology.

[71]  M. Hung,et al.  Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition , 2004, Nature Cell Biology.

[72]  I. Amit,et al.  LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation , 2004, The EMBO journal.

[73]  A. Holmgren,et al.  Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. , 2004, Antioxidants & redox signaling.

[74]  R. Henriksson,et al.  LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT–PCR and immunohistochemical analysis , 2003, British Journal of Cancer.

[75]  M. Tsurudome,et al.  The targeted disruption of the CD98 gene results in embryonic lethality. , 2003, Biochemical and biophysical research communications.

[76]  G. Scagliotti,et al.  Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. , 2003, Lung cancer.

[77]  Huang Shao,et al.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.

[78]  M. Hung,et al.  β-catenin interacts with and inhibits NF-κB in human colon and breast cancer , 2002 .

[79]  S. Bröer Adaptation of plasma membrane amino acid transport mechanisms to physiological demands , 2002, Pflügers Archiv.

[80]  R. Martindale,et al.  Cloning and functional characterization of a new subtype of the amino acid transport system N. , 2001, American journal of physiology. Cell physiology.

[81]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[82]  R. Martindale,et al.  Structure, function, and tissue expression pattern of human SN2, a subtype of the amino acid transport system N. , 2001, Biochemical and biophysical research communications.

[83]  M. Nau,et al.  cbl-b inhibits epidermal growth factor receptor signaling , 1999, Oncogene.

[84]  V. Ganapathy,et al.  Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function. , 1999, Biochemical and biophysical research communications.

[85]  R. Lotan,et al.  Molecular Cloning and Characterization of a Novel Retinoic Acid-inducible Gene That Encodes a Putative G Protein-coupled Receptor* , 1998, The Journal of Biological Chemistry.

[86]  H. Koeffler,et al.  Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. , 1996, Cancer research.

[87]  P. Taylor Role of amino acid transporters in amino acid sensing. , 2014, The American journal of clinical nutrition.

[88]  S. Bröer The SLC38 family of sodium–amino acid co-transporters , 2013, Pflügers Archiv - European Journal of Physiology.

[89]  R. Ciurea,et al.  EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors. , 2012, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[90]  M. Yuen,et al.  Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract. , 2011, Experimental and therapeutic medicine.

[91]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[92]  V. Ganapathy,et al.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.

[93]  V. Ganapathy,et al.  Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[94]  V. Ganapathy,et al.  Cellular uptake of amino acids: Systems and regulation , 2003 .

[95]  M. Hung,et al.  beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. , 2002, Cancer cell.